Shadia I. Jalal

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Corey J. Langer, Shirish M. Gadgeel, Hossein Borghaei et al. · The Lancet Oncology · 2016 · 1.4K citations

Oncology, Metronomic Therapy, Pathology +7

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · Journal of the National Comprehensive Cancer Network · 2023 · 450 citations · Full text

Esophageal Cancer, Immunology, Gastroenterology +17

Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

Hyun Cheol Chung, Sarina A. Piha‐Paul, José A. López-Martín et al. · Journal of Thoracic Oncology · 2019 · 427 citations · Full text

Safety and Antitumor Activity of the Anti–Programmed Death-1 Antibody Pembrolizumab in Patients With Advanced Esophageal Carcinoma

Toshihiko Doi, Sarina A. Piha‐Paul, Shadia I. Jalal et al. · Journal of Clinical Oncology · 2017 · 315 citations · Full text

Antitumor Activity, Esophageal Cancer, Immunology +19

Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study

Yung‐Jue Bang, Yoon‐Koo Kang, Daniel V.T. Catenacci et al. · Gastric Cancer · 2019 · 242 citations · Full text